Deprescribing Research: Real Outcomes of Reducing Medications in 2026

Imagine taking six pills every morning and four at night. You’ve been told these are necessary for your blood pressure, cholesterol, sleep, and joint pain. But lately, you feel more tired than rested, dizzy when you stand up, and confused about which pill does what. This isn’t just a hypothetical scenario-it’s the daily reality for millions of older adults. The medical term for this is polypharmacy, defined as the concurrent use of multiple medications, typically five or more, by a single patient. And the emerging solution? Deprescribing.

Deprescribing isn’t just “stopping drugs.” It’s a deliberate, evidence-based process to reduce or stop medications that may be causing harm or no longer provide benefit. Recent research shows that while the concept sounds simple, the outcomes are complex. Some studies show dramatic improvements in quality of life; others show minimal change in hospital admissions. So, what does the data actually say about reducing medications?

The Core Definition: What Is Deprescribing?

To understand the outcomes, we first need to define the practice. According to the American Geriatrics Society (AGS), deprescribing is the planned and supervised process of dose reduction or stopping of medication that might be causing harm, or no longer be of benefit. This definition, updated in 2023, emphasizes two key points: it must be supervised, and it focuses on harm reduction rather than just pill count.

This differs from simply forgetting to refill a prescription. It requires a multidimensional evaluation of the patient’s actual function, life expectancy, and personal preferences. For example, a 75-year-old with advanced dementia and limited mobility might not benefit from aggressive statin therapy aimed at preventing heart attacks decades down the line. In such cases, deprescribing shifts the focus from long-term prevention to immediate comfort and safety.

• Identify: Review all current medications for necessity.
• Evaluate: Determine if benefits outweigh risks given current health status.
• Taper: Gradually reduce dosage to avoid withdrawal symptoms.
• Monitor: Watch for symptom recurrence or adverse effects.
• Document: Record outcomes to guide future decisions.

What Does the Latest Research Say About Outcomes?

In March 2023, a major systematic review and meta-analysis published in JAMA Network Open analyzed data from numerous trials involving community-dwelling older adults. The findings were nuanced. On average, deprescribing interventions reduced the mean number of medications from a baseline of 9.74. However, the individual impact was modest: approximately seven patients needed intervention to reduce just one prescribed medication per person.

Does that mean deprescribing doesn’t work? Not necessarily. Think of it like cancer screening. The benefit for any single individual might seem small, but when applied across a population of thousands, the cumulative effect is significant. A primary care clinician with 2,000 patients-half of whom meet criteria for polypharmacy-could potentially reduce 140 unnecessary medications through structured deprescribing programs. That’s fewer side effects, lower costs, and less confusion for hundreds of people.

However, other studies paint a different picture. A 2013 analysis in the Canadian Journal of Hospital Pharmacy noted that while deprescribing successfully reduced medication usage and costs, few studies found statistically significant differences in functional outcomes, hospital admissions, or mortality rates. Researchers attributed this lack of clear clinical improvement to short follow-up periods and insufficient statistical power in most trials. Essentially, we know we can stop pills, but proving that stopping them extends life or prevents falls remains challenging.

Who Benefits Most From Deprescribing?

Not everyone needs to cut back on medications. Deprescribing is particularly critical for specific groups where the risk of drug interactions and side effects outweighs potential benefits. Research highlights several high-priority populations:

• Patients with Advanced Disease: Those with terminal illness or severe frailty often take preventive medications that offer no meaningful improvement in their remaining lifespan.
• Individuals with Severe Dementia: Cognitive decline changes how drugs are metabolized and perceived. Many psychotropic medications used in dementia care have black box warnings due to increased mortality risk.
• Those Experiencing Adverse Drug Reactions: New symptoms like dizziness, confusion, or fatigue may be side effects rather than new diseases. Identifying and removing the culprit drug can resolve these issues without adding more treatment.
• Polypharmacy Patients: Older adults taking ten or more medications face exponentially higher risks of drug-drug interactions. Simplifying regimens reduces this complexity.

For instance, proton pump inhibitors (PPIs) are commonly prescribed for acid reflux. Long-term use has been linked to bone fractures and kidney issues. Studies suggest many patients can safely taper off PPIs if lifestyle changes are implemented, yet they often remain on them indefinitely because no one revisits the original indication.

The Implementation Challenge: Why Is It Hard?

If deprescribing is so beneficial, why isn’t it happening everywhere? The answer lies in systemic and psychological barriers. First, there’s the “prescriber inertia.” Doctors are trained to add treatments, not remove them. Stopping a medication feels risky because if a condition worsens, the prescriber might be blamed. As Dr. Dan Gnjidic, a leading researcher in this field, notes, deprescribing requires the same professional rigor as prescribing, including informed consent and close monitoring.

Second, patients are often reluctant to stop medications. They view pills as symbols of care and protection. The American Academy of Family Physicians reports that patients generally want to take fewer medications but rarely initiate the conversation. They expect clinicians to lead. This creates a stalemate: doctors hesitate to start the discussion, and patients wait for permission to stop.

Third, hospital settings complicate matters. Hospital stays are often too short to see the full effects of medication changes. A patient might be discharged after having a beta-blocker stopped, only to experience rebound hypertension weeks later at home. Effective deprescribing requires seamless coordination between hospitalists and primary care providers, which is frequently lacking in fragmented healthcare systems.

How to Start: A Practical Framework for Clinicians and Patients

Implementing deprescribing doesn’t require a complete overhaul of medical practice. It starts with a shift in mindset. Here’s a practical approach based on guidelines from the Institute for Healthcare Improvement (IHI) and the AGS:

1. Conduct a Comprehensive Medication Review: Don’t just look at the list. Ask why each drug was started, what problem it solves, and whether that problem still exists. Use tools like the Beers Criteria to identify potentially inappropriate medications (PIMs).
2. Set Shared Goals: Talk to the patient. What matters most to them right now? Is it walking to the mailbox, staying independent, or avoiding hospital visits? Align medication goals with these priorities.
3. Stop One Drug at a Time: Changing multiple medications simultaneously makes it impossible to determine which change caused any new symptoms. Taper slowly, especially with benzodiazepines, opioids, and antidepressants, to avoid withdrawal.
4. Monitor Closely: Schedule follow-up appointments specifically to assess the effects of deprescribing. Document both positive outcomes (e.g., improved energy) and negative ones (e.g., return of pain).
5. Engage Pharmacists: Pharmacists are medication experts. Involve them in the decision-making process to manage interactions and dosing strategies.

Recent pilot programs using electronic health record (EHR) alerts have shown promise. By flagging patients with high medication burdens or known PIMs during routine visits, clinicians can initiate conversations more naturally. One study reported a 15% reduction in PIMs in clinics using these digital tools compared to control groups.

The Future of Deprescribing Research

As the U.S. population ages-with the CDC projecting that 20% of Americans will be 65 or older by 2030-the demand for effective deprescribing strategies will grow. Current research is moving beyond simple medication counts toward more sophisticated endpoints. Scientists are exploring genetic factors that influence drug metabolism, aiming to personalize deprescribing plans. For example, certain genetic markers may indicate a higher risk of side effects from specific antidepressants, guiding safer withdrawal protocols.

There is also a push for longer-term studies. Most existing trials last only six to twelve months. We need data spanning years to understand the true impact on mortality, cognitive decline, and overall longevity. Until then, deprescribing remains a best-practice recommendation supported by moderate-quality evidence, rather than a guaranteed cure-all.

Ultimately, deprescribing is about respecting the patient’s body and life stage. It acknowledges that medicine is not static. What worked ten years ago might not be appropriate today. By embracing this dynamic approach, healthcare providers can help patients live not just longer, but better.